

O I P E
FEB 03 2005
PATENT TRADEMARK OFFICE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/049,556
Filing Date	February 12, 2002
Intern. Application Number	PCT/AU00/00982
Intern. Filing Date	08/17/00
First Named Inventor	DAVID G. LITTLE
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	RICE006

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY
		Office ³	Number ⁴		
Ks	B7	WO96/39150A		Merck & Co., Inc.	12/12/1996

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
Ks	C1	ABSTRACT: LOMBARDI, entitled "Clinical trials with bisphosphonates" Ann Ital Med Int. 1992 Jul-Sep; 7(3 Suppl): 158S-165S.			
Ks	C2	GOODSHIP et al., entitled "Use of Bisphosphonate (pamidronate) to modulate fracture repair in ovine bone," Ann Oncology 1994; 5 Suppl 7:S53-5.			
Ks	C3	LI et al. entitled "Effect of Bisphosphonate (Incadronate) on Fracture Healing of Long Bones in Rats," J Bone Miner Res. Vol. 14, Number 6, (1999): 969-79.			
Ks	C4	RUSSELL et al., entitled "Bisphosphonates: from the laboratory to the clinic and back again," Bone 1999 Jul; 25(1):97-106			
Ks	C5	GLORIEUX et al., entitled "Cyclic administration of pamidronate in children with severe osteogenesis imperfecta," N. Engl. J Med 1998; Number 14, 339:947-52			
Ks	C6	RAGGIO et al. entitled, "Alendronate reduces fractures without increasing bone strength in a growing mouse model of osteogenesis imperfecta," Proceedings of Paediatric Orthopaedic Society of North America May 1999. (Paper No. 66)			
Ks	C7	GIULIANI et al., entitled "Bisphosphonates Stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo," Bone 1998, May; Vol. 22 (5): 455-61.			
Ks	C8	MAYOR P., et al., entitled "Zoledronic acid is superior to pamidronate in the treatment of tumour-induced hypercalcaemia: a pooled analysis," Journal of Clinical Oncology, Vol. 19, No. 2, January 15, 2001: pp. 558-567			

Examiner Signature	S.R.L.H.-K	Date Considered	04/17/06
--------------------	------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

O P E
FEB 03 2005
SEARCHED INDEXED
P A T E N T & T R A D E M A R K S
Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	1	of	1	Application Number	10/049,556
				Filing Date	May 7, 2002
				First Named Inventor	LITTLE, DAVID GRAHAM
				Group Art Unit	1617
				Examiner Name	CRIARES, THEODORE J.
				Attorney Docket Number	RICE-006

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
K		5,853,759		Katdare et al.	12-29-1998

FOREIGN PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)	

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			

Examiner Signature	<i>S. Little '06</i>	Date Considered	04/17/06
--------------------	----------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	1	of	1	Application Number	Unassigned
				Filing Date	Herewith
				First Named Inventor	LITTLE, DAVID G.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	RICE-006

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY
		Office ³	Number ⁴	Kind Code ⁵ (if known)		
Ks	B1	WO	93/11786		Procter & Gamble Pharmaceuticals, Inc.	06/24/1993
Ks	B2	WO	94/21266		Leiras Oy	09/24/1994
Ks	B3	WO	95/28936		Merck & Co., Inc.	11/02/1995
Ks	B4	WO	96/39150		Merck & Co., Inc.	12/12/1996
Ks	B5	WO	96/39151		Merck & Co., Inc.	12/12/1996
Ks	B6	WO	98/00438		The University of Liverpool	01/08/1998

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published				

Examiner Signature	S2/MH '1C	Date Considered	04/17/06
--------------------	-----------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.